AtriCure PT Raised to $16.00 at Canaccord Genuity (ATRC)
Stock analysts at Canaccord Genuity raised their target price on shares of AtriCure (NASDAQ:ATRC) from $14.00 to $16.00 in a report issued on Wednesday, Analyst Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target points to a potential upside of 15.94% from the company’s current price.
Shares of AtriCure (NASDAQ:ATRC) traded up 10.84% during mid-day trading on Wednesday, hitting $13.80. 335,111 shares of the company’s stock traded hands. AtriCure has a 52 week low of $5.90 and a 52 week high of $10.18. The stock has a 50-day moving average of $9.55 and a 200-day moving average of $8.99. The company’s market cap is $289.5 million.
AtriCure (NASDAQ:ATRC) last announced its earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. The company had revenue of $20.10 million for the quarter, compared to the consensus estimate of $18.30 million. During the same quarter in the previous year, the company posted ($0.16) earnings per share. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. Analysts expect that AtriCure will post $-0.46 EPS for the current fiscal year.
AtriCure, Inc, is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.